641
Participants
Start Date
October 31, 2012
Primary Completion Date
April 30, 2015
Study Completion Date
April 30, 2015
florbetapir (18F)
Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
Research Site, Patchogue
Research Site, Marseille
Research Site, Genoa
Research Site, Genoa
Research Site, Milan
Research Site, Brescia
Research Site, Milan
Research Site, Milan
Research Site, Milan
Research Site, Monza
Research Site, Dijon
Research Site, Bergamo
Research Site, Brescia
Research Site, Greensboro
Research Site, Durham
Research Site, Toulouse
Research Site, Orlando
Research Site, Bordeaux
Research Site, Miami Beach
Research Site, West Palm Beach
Research Site, Pessac
Research Site, Clearwater
Research Site, Montpellier
Research Site, Padua
Research Site, Tours
Research Site, Modena
Research Site, Parma
Research Site, Nantes
Research Site, Florence
Research Site, Reims
Research Site, Nancy
Research Site, Pisa
Research Site, Lille
Research Site, Strasbourg
Research Site, Villeurbanne
Research Site, Bron
Research Site, Shreveport
Research Site, Paris
Research Site, Rouen
Research Site, Amiens
Research Site, Salt Lake City
Research Site, Phoenix
Research Site, Phoenix
Research Site, Scottsdale
Research Site, Sun City
Research Site, Las Vegas
Research Site, Las Vegas
Research Site, Boston
Research Site, Chestnut Hill
Research Site, Quincy
Research Site, Providence
Research Site, Providence
Research Site, Bennington
Research Site, Nice
Research Site, Perugia
Research Site, Rome
Research Site, Rome
Lead Sponsor
Eli Lilly and Company
INDUSTRY
Avid Radiopharmaceuticals
INDUSTRY